Preventing infections in patients undergoing hemodialysis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 6, 2010, Pages 643-655

  Kallen, Alexander J ^a   Arduino, Matthew J ^a   Patel, Priti R ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Bloodstream infection; Hemodialysis; Hepatitis C; Infection control

Indexed keywords

ALCOHOL; ANTIFOULING AGENT; ANTIINFECTIVE AGENT; BACITRACIN; CHLORHEXIDINE GLUCONATE; DISINFECTANT AGENT; GENTAMICIN; GRAMICIDIN; HEPATITIS B VACCINE; INFLUENZA VACCINE; POLYMYXIN B; POVIDONE IODINE; PRESERVATIVE; PSEUDOMONIC ACID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CENTRAL VENOUS CATHETER; DISEASE SURVEILLANCE; ENVIRONMENTAL SANITATION; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HONEY; HUMAN; HYGIENE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INJECTION; KIDNEY FAILURE; NONHUMAN; REVIEW; RISK FACTOR; STAFF TRAINING; STAPHYLOCOCCUS INFECTION; VACCINATION; VIRUS TRANSMISSION;

AMBULATORY CARE; BACTEREMIA; BACTERIAL INFECTIONS; HEPATITIS, VIRAL, HUMAN; HUMANS; INFECTION CONTROL; INFLUENZA, HUMAN; RENAL DIALYSIS; VIRUS DISEASES;

EID: 77953240175     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.47     Document Type: Review

References (84)

1. Haley RW, Culver DH, White JW et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am. J. Epidemiol. 121, 182-205 (1985).
2. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2009).
3. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb. Mortal. Wkly Rep. 50 (RR-5), 1-43 (2001).
4. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for vascular access, 2000. Am. J. Kidney Dis. 37, S137-S181 (2001).
5. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy, and vascular access. Am. J. Kidney Dis. 48, S1-S322 (2006).
6. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morb. Mortal. Wkly Rep. 51 (RR-10), 1-29 (2002).
7. Boyce JM, Pittet D. Guidelines for hand hygiene in health-care settings. MMWR Morb. Mortal. Wkly Rep. 51 (RR-16), 1-45 (2002).
8. George A, Tokars JI, Clutterbuck EJ, Bamford KB, Pusey C, Holmes AH. Reducing dialysis associated bacteraemia, and recommendations for surveillance in the United Kingdom: prospective study. Br. Med. J. 332, 1435-1439 (2006).
9. Centers for Disease Control and Prevention. Hepatitis: control measures for hepatitis B in dialysis centers. In: Viral Hepatitis Investigations and Control Series. CDC, Atlanta, GA, USA (1977).
10. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am. J. Kidney Dis. 33, 356-360 (1999).
11. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial. 18, 52-61 (2005).
12. Bond TC, Patel PR, Krisher J et al. Association of standing-order policies with vaccination rates in dialysis clinics: a US-based cross-sectional study. Am. J. Kidney Dis. 54, 86-94 (2009).
13. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144, 705-714 (2006).
14. Thompson ND, Novak RT, Datta D et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect. Control Hosp. Epidemiol. 30, 900-903 (2009).
15. Girou E, Chevaliez S, Challine D et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin. Infect. Dis. 47, 627-633 (2008).
16. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, 2009. MMWR Morb. Mortal. Wkly Rep. 58(RR-8), 1-52 (2009).
17. Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int. 63, 738-743 (2003).
18. Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, 2009. MMWR Morb. Mortal. Wkly Rep. 57 (2009).
19. Pearson ML, Bridges CB, Harper SA. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep. 55 (RR-2), 252 (2006).
20. Saxon H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr. Inf. Dis. J. 18, 779-783 (1999).
21. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect. Control Hosp. Epidemiol. 25, 923-928 (2004).
22. Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of health care workers in long-term care hospitals reduces the mortality of elderly patients. J. Infect. Dis. 175, 1-6 (1997).
23. Lemaitre M, Meret T, Rothan-Tondeur M et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J. Am. Geriatr. Soc. 57, 1580-1586 (2009).
24. Tapiainen T, Bar G, Schaad UB, Heininger U. Influenza vaccination among healthcare workers in a university children's hospital. Infect. Contr. Hosp. Epidemiol. 26, 855-858 (2005).
25. Wodi AP, Samy S Ezeanolue E et al. Influenza vaccine: immunization rates, knowledge, and attributes of resident physicians in an urban teaching hospital. Infect. Control Hosp. Epidemiol. 26, 867-873 (2005).
26. Goldstein AO, Kincade JE, Gamble G, Bearman RS. Policies and practices for improving influenza immunization rates among healthcare workers. Infect. Control Hosp. Epidemiol. 25, 908-911 (2004).
27. Kallen AJ, Fiore AE. Overcoming challenges to influenza vaccination in patients with CKD. Am. J. Kidney Dis. 54, 6-9 (2009).
28. Engemann JJ, Friedman JY, Reed SD et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect. Control Hosp. Epidemiol. 26, 534-539 (2005).
29. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck TC, Horan TC. Dialysis surveillance report: National Healthcare Safety Network - data summary for 2006. Semin. Dial. 21, 24-28 (2008).
30. Dopirak M, Hill C, Oleksiw M et al. Surveillance of hemodialysis- associated primary bloodstream infections: the experience of ten hospital-based centers. Infect. Control Hosp. Epidemiol. 23, 721-724 (2002).
31. Lok CE. Fistula first initiative: advantages and pitfalls. Clin. J. Am. Soc. Nephrol. 2, 1043-1053 (2007).
32. Hoffman KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing: a meta-analysis of the infection risks. JAMA 267, 2072-2076 (1992).
33. Gillies D, Carr D, Frost J, O'Riordan E, Gunning R, O'Brien I. Gauze and tape and transparent polyurethane dressings for central venous catheters. Cochrane Database Syst. Rev. 3, CD003827 (2003).
34. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338, 339-343 (1991).
35. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann. Intern. Med. 136, 792-801 (2002).
36. Mimoz O, Pieroni L, Lawrence C et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit. Care Med. 24, 1818-1823 (1996).
37. Ash SR. The evolution and function of central venous catheters for dialysis. Semin. Dial. 14, 416-424 (2001).
38. Romero-Gómez MP, Quiles-Melero MI, Peña Garcia P et al. Outbreak of Burkholderia cepecia bacteremia caused by contaminated chlorhexidine in a hemodialysis unit. Infect. Control Hosp. Epidemiol. 29, 377-378 (2008).
39. Kaitwatcharachai C, Silpapojakul K, Jitsurong S, Kalnauwakul S. An outbreak of Burkholderia cepecia bacteremia in hemodialysis patients: an epidemiologic and molecular study. Am. J. Kidney Dis. 36, 199-204 (2000).
40. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone iodine. Kidney Int. 40, 934-938 (1991).
41. Sesso R, Barbosa D, Leme IL et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J. Am. Soc. Nephrol. 9, 1085-1092 (1998).
42. Johnson DW, van Eps C, Mudge DW et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J. Am. Soc. Nephrol. 16, 1456-1462 (2005).
43. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J. Am. Soc. Nephrol. 13, 169-179 (2003).
44. James MT, Conley J, Tonelli M, Manns BJ, Macrae J, Hemmelgarn BR. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann. Intern. Med. 148, 596-605 (2008).
45. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized controlled trials. Clin. Infect. Dis. 47, 83-93 (2008).
46. Jaffer Y, Shelby NM, Taal MW, Fluck RJ, McIntyre CW. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am. J. Kidney Dis. 51, 233-241 (2008).
47. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol. Dial. Transplant 23, 1666-1672 (2007).
48. Abbas SA, Haloob IA, Taylor SL et al. Effect of antimicrobial locks for tunneled hemodialysis catheters on bloodstream infection and bacterial resistance: a quality improvement report. Am. J. Kidney Dis. 53, 492-502 (2009).
49. Dankert J, Uitentuis J, Houwen B, Tegzess AM, van der Hem GK. Hepatitis B surface antigen in environmental samples from hemodialysis units. J. Infect. Dis. 134, 123-127 (1976).
50. Favero MS, Maynard JE, Petersen NJ et al. Letter: Hepatitis-B antigen on environmental surfaces. Lancet 2, 1455 (1973).
51. Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab. Sci. 14, 235-252 (1977).
52. Froio N, Nicastri E, Comandini UV et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am. J. Kidney Dis. 42, 546-550 (2003).
53. Arduino MJ. Dialysis-associated complications and their control. In: Bennett and Brachman's Hospital Infections. Jarvis WR (Ed.). Lippincott Williams & Wilkins, PA, USA, 339-379 (2007).
54. Snydman DR, Bryan JA, London WT et al. Transmission of hepatitis B associated with hemodialysis: role of malfunction (blood leaks) in dialysis machines. J. Infect. Dis. 134, 562-570 (1976).
55. Tokars JI, Arduino MJ, Alter MJ. Infection control in hemodialysis units. Infect. Dis. Clin. North Am. 15, 797-812 (2001).
56. Weber DJ, Barbee SL, Sobsey MD, Rutala WA. The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound. Infect. Control Hosp. Epidemiol. 20, 821-827 (1999).
57. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Non-hospital health care-associated hepatitis B and C virus transmission, United States, 1998-2008. Ann. Intern. Med. 150, 33-39 (2009).
58. Grohskopf LA, Roth VR, Feiken DR et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N. Engl. J. Med. 344, 1491-1497 (2001).
59. Centers for Disease Control and Prevention. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb. Mortal. Wkly Rep. 57, 875-876 (2008).
60. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763-1771 (2007).
61. Kutty PK, Benoit SR, Woods CW et al. Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005. Infect. Control Hosp. Epidemiol. 29, 197-202 (2008).
62. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119(2 Suppl.), 397S-404S (2001).
63. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29, 996-1011 (2008).
64. Centers for Disease Control and Prevention. Invasive methicillin- resistant Staphylococcus aureus infections among dialysis patients, United States, 2005. MMWR Morb. Mortal. Wkly Rep. 56, 197-199 (2007).
65. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46, 668-674 (2008).
66. Finks J, Wells E, Dyke TL et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg. Infect. Dis. 15, 943-945 (2009).
67. Hadley AC, Karchmer TB, Russell GB, McBride DG, Freedman BI. The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am. J. Nephrol. 27, 352-359 (2007).
68. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 197, 1226-1234 (2008).
69. Pop-Vicas A, Strom J, Stanley K, D'Agata EMC. Multidrug-resistant Gram-negative bacteria among patients who require chronic hemodialysis. J. Am. Soc. Nephrol. 3, 752-758 (2008).
70. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infections in patients on hemodialysis. N. Eng. J. Med. 315, 91-96 (1986).
71. Engemann JJ, Friedman JY, Reed SD et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect. Control Hosp. Epidemiol. 26, 534-539 (2005).
72. Nissenson AR, Dylan ML, Griffiths RI et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am. J. Kidney Dis. 46, 301-308 (2005).
73. Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect. Control Hosp. Epidemiol. 26, 916-922 (2005).
74. Trautmann M, Stecher J, Hemmer W, Luz K, Pankin HT. Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. Chemotherapy 54, 9-16 (2008).
75. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect. Control Hosp. Epidemiol. 17, 793-797 (1996).
76. Boelaert JR, DeSmedt RA, DeBaere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol. Dial. Transplant. 4, 278-281 (1989).
77. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol. Dial. Transplant. 8, 235-239 (1993).
78. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EMC. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin. Infect. Dis. 37, 1629-1638 (2003).
79. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Eng. J. Med. 346, 1871-1877 (2002).
80. Jones JC, Rogers TJ, Brookmeyer P et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin. Infect. Dis. 45, 541-547 (2007).
81. Edmond MB, Bearman GML. Mandatory public reporting in the USA: an example to follow? J. Hosp. Infect. 65, 182-188 (2007).
82. Centers for Disease Control and Prevention. Reduction of central line-associated bloodstream infections among patients in intensive care units, Pennsylvannia, April 2001-March 2005. MMWR Morb. Mortal. Wkly Rep. 54, 1013-1016 (2005).
83. Pronovost P, Needham D, Berenholtz S et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N. Eng. J. Med. 355, 2725-2732 (2006).
84. CDC. Transmission of hepatitis B and C viruses in outpatient settings, New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb. Mortal. Wkly Rep. 52, 901-906 (2003).